ROARABLE
FREE $100K
Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / CNMD / insiders
CBLL (43) TMDX (61) INMD (57) AXGN (53) ⌘ Pro Terminal β†’

CONMED Corporation (CNMD) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$46.59 +5.19% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $46.94

CONMED Corporation (CNMD) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C β€’ HOLD / WATCH Cap $1.32B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CNMD Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is CNMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, CONMED Corporation (NYSE: CNMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $46.59 (+5.19% 1D, market cap $1.32B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, CNMD ranks #149 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does CNMD compare to CBLL and TMDX in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), CNMD carries a Roarable C (62/100 RQD), trailing P/E of 28.9x, gross margin of 54.6%, and ROIC of 7.8%. By comparison, CBLL (CeriBell Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $1.02B) and TMDX (TransMedics Group Inc.) posts a C- grade (61/100 RQD, P/E 12.2x, ROIC 18.1%, cap $2.29B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CNMD?
β–Ό

Per CNMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000816956), CONMED Corporation generated $1.37B in revenue (+5.2% YoY), $47.1M in net income, and $150.9M in free cash flow against $2.33B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $46.93 (+0.74%)🧬 Cannibal Buyback (-2.08% YoY Shares)βš™οΈ Cash Engine: 13/20 (C) β€’ 11% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY β€’ 54.3% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERHOLD / WATCH β€’ C
025507510062
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ Β· Rk C+
Cash (13)Whales (7)SEC (14)Macro (13)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+1.8% Base Target
$56 Bull$47 Base$37 Bear
πŸ“¬ FREE CNMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for CNMD)Realized 20D OHLCV Swing Band: Β±8.4%
Deterministic 5-Pillar Attribution (62/100 Composite)
πŸ” WHY CNMD SCORES 62/100 (C) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy β€’ Cannibal Buyback (-2.08% YoY Shares)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (23% of score)

Altman Z-Score 1.91 (WATCH ZONE (1.8–3.0)) β€’ Piotroski F-Score 7/9

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
54
Grade C-$45.55+4.5% Next Q
Q2 (-2Q)
57
Grade C$47.58-0.8% Next Q
Q3 (-1Q)
59
Grade C$47.20-1.3% Next Q
Current
62
Grade C$46.59+0.7% Hist 90D Ξ±
Trajectory: C- (54) β†’ C (62)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the CNMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 62/100 (C) score, CNMD faces multiple-compression risk if 28.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) β€” any gross margin slip below 52.1% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($46.82) or 200D SMA ($41.44) invalidates the momentum regime and cuts Target Base ($47.43) toward Bear Floor ($37.00).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CNMDβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œCNMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 62%NO 38%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

CNMD Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CNMD)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CNMD. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (CNMD Tape Review)

  • βœ“Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • βœ“Forensic Red-Light accounting & dilution traps to review on your watchlist
  • βœ“Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
CNMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +29.85%πŸ“ WEDGE COMPRESSION COIL
2026-11-03O $45.72H $46.59L $44.29C $46.59VOL 404.1K
RES: $49.33SUP: $43.90SMA50: $46.82SMA200: $41.44
$55.22$48.77$42.33$35.88$29.44RES $49.33SUP $43.90$46.592026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CNMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ CNMD Butterfly Map β†’ + Track CNMD β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
22.2%/yr Implied 5Y Growth

vs. +5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CNMD today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for CNMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CNMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CNMD)

Health Care Rank #149 of 1015 βš”οΈ CBLL vs CNMD Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (CNMD vs. CBLL, TMDX, INMD, AXGN)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, CONMED Corporation (CNMD) ranks #149 by composite RQD confidence (62/100, grade C) and #321 by equity capitalization ($1.32B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. CNMD currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CNMD ACTIVE
CONMED Corporation
C 62/100 28.9x 54.6% 7.8% +5.19% $1.32B Benchmark Subject
CBLL
CeriBell Inc.
D- 43/100 β€” 87.9% -35.0% +1.43% $1.02B /cbll-vs-cnmd β†’
TMDX
TransMedics Group Inc.
C- 61/100 12.2x 59.9% 18.1% +1.03% $2.29B /tmdx-vs-cnmd β†’
INMD
InMode Ltd.
D+ 57/100 β€” 78.5% 17.7% +3.63% $759.9M /inmd-vs-cnmd β†’
AXGN
Axogen Inc.
D+ 53/100 β€” 74.3% -2.6% +0.97% $2.95B /axgn-vs-cnmd β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0000816956 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CONMED Corporation (CNMD) reported GAAP revenue of $1.37B (+5.2% vs. FY2024 revenue of $1.31B , and +10.4% cumulative change since FY2023) , GAAP net income of $47.1M, operating cash flow of $170.7M, and free cash flow of $150.9M (-2.0% YoY). On the balance sheet, CNMD closed FY2025 with $2.33B in total assets against $0 in total debt (Altman Z-Score: 1.91, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.37B $47.1M $170.7M $150.9M $2.33B β€”
FY2024 (FY) 2024-12-31 $1.31B $132.4M $167.0M $153.9M $2.31B β€”
FY2023 (FY) 2023-12-31 $1.24B $64.5M $125.3M $125.3M β€” β€”

3. CNMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CNMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, CONMED Corporation (NYSE: CNMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $46.59 (+5.19% 1D, market cap $1.32B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, CNMD ranks #149 in composite RQD confidence.

How does CNMD compare to CBLL and TMDX in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), CNMD carries a Roarable C (62/100 RQD), trailing P/E of 28.9x, gross margin of 54.6%, and ROIC of 7.8%. By comparison, CBLL (CeriBell Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $1.02B) and TMDX (TransMedics Group Inc.) posts a C- grade (61/100 RQD, P/E 12.2x, ROIC 18.1%, cap $2.29B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CNMD?

Per CNMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000816956), CONMED Corporation generated $1.37B in revenue (+5.2% YoY), $47.1M in net income, and $150.9M in free cash flow against $2.33B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CNMD trading relative to its 50-day, 200-day, and 52-week technical levels?

CNMD last traded at $46.59 (+5.19% on volume of 444,288 shares), positioning the stock -0.49% below its 50-day simple moving average ($46.82) and +12.43% above its 200-day simple moving average ($41.44). Across its 52-week range of $31.44 to $53.66, CNMD sits at the 68.2% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of Β±8.4% ($42.68 to $50.50).

Direct Sub-Reports: CNMD RQD Cockpit CNMD 12M Forecast CNMD Earnings & Move CNMD Dividends & DRIP CNMD Insiders & 13F CNMD Whale Options CNMD Profit Sankey CNMD News & Why
ROARABLE RATING BRIEF β€’ RQD 62/100 (C) βœ“ SEC XBRL & RQD VERIFIED

CNMD β€” CONMED Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

CONMED Corporation (CNMD) earns a live Roarable RQD composite score of 62/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $46.59 (+5.19% 1D, market capitalization $1.32B).

  • Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 7.8%, gross margin of 54.6%, operating margin of 7.5%, and free cash flow yield of 11.07%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (13/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 1.91, Piotroski F-Score of 7/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

CONMED Corporation (CNMD) is listed on the NYSE in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. Gross margin of 54.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), CONMED Corporation (CNMD) reported $1.37B in annual revenue (up from $1.31B in FY2024, +5.2% YoY) and $47.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.24B revenue, $64.5M net income) through FY2025, CNMD scaled operating cash flow to $170.7M and free cash flow to $150.9M, backed by $2.33B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (C β€’ RQD 62/100): Company leadership has skin in the game with net positive insider conviction. Free cash flow yield of 11.07% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $31.44 – $53.66 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 28.9x trailing P/E and 11.4x EV/EBITDA against 7.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore contains no upstream or downstream dependency mapping, no sector correlation data beyond the sector and industry labels, and no identified 2nd-order bottlenecks. Investors should treat supply-chain exposure as unverified from this dataset.

  • Key Question #1: Can CNMD sustain or expand its 7.5% operating margin and 7.8% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.37B and free cash flow of $150.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CNMD's 26.9x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CNMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for CONMED Corporation (CNMD) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to CNMD Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CNMD Bull vs. Bear Conversation Board β€” What's Your Call at $46.59?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CNMD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CNMD:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER β€’ Institutional Buy-Side πŸ‚ BULLISH 🎯 Target: $52.71 (+19.0%)
πŸ“Œ Pinned Debate

Free cash flow yield of 11.07% and a Piotroski F-Score of 7/9 indicate strong cash generation relative to the market price.

Don't sleep on CNMD's setup in Health Care. Free cash flow yield of 11.07% and a Piotroski F-Score of 7/9 indicate strong cash generation relative to the market price.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (62/100) backs up the fundamental quality.

RetailWhale_TX πŸ‚ BULL

@MeanReversion_88 Shorting a 7/20 institutional whale-flow stock at $44.29 is dangerous when funds are rotating into Health Care.

ME MeanReversion_88 RQD DEBATE OPENER β€’ Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $36.76 (-17.0%)
Spot @ $44.29

Net income fell from $132.4M in FY 2024 to $47.1M in FY 2025 while trailing P/E remains elevated at 28.9.

I respect the product at CONMED Corporation, but the stock at $44.29 is a different story. Net income fell from $132.4M in FY 2024 to $47.1M in FY 2025 while trailing P/E remains elevated at 28.9.. FCF yield is 11.07% and RQD sits at 62/100 (C) β€” why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%